Drug intelligence / Profile preview

Hemopatch

Development stage
Unknown
Lead developer
Takeda
Administration
Surgical, Implant
01

Overview

Hemopatch is a ready-to-use, absorbable collagen pad designed as a surgical hemostatic device and sealant. It consists of a soft, thin, flexible pad made from bovine-derived collagen coated with N-hydroxysuccinimide functionalized polyethylene glycol (NHS-PEG). Upon application to moist tissue during surgery, the NHS-PEG coating rapidly forms covalent bonds with tissue proteins in the presence of wound fluid (such as blood or lymph), creating an adhering hydrogel that seals the surface. Simultaneously, the bovine collagen induces platelet activation and provides a scaffold for fibrin clot formation to achieve hemostasis. The product is fully absorbed by host tissue within 6–8 weeks post-implantation. Hemopatch is indicated for use in controlling mild or moderate bleeding and sealing leaks of body fluids or air when conventional surgical techniques are ineffective or impractical. It can be used across various soft tissues—including cardiovascular, connective tissue, parenchyma, serosa, viscera—and for dura closure in neurosurgery following trauma or excision[1][2][5][6]. Clinical studies have demonstrated its effectiveness in reducing postoperative complications such as leaks and blood loss[5][7][8].

Brand names
Hemopatch
Other names
Hemopatch Sealing HemostatHEMOPATCH Sealing Hemostat RT
02

Targets

Exposed alpha- and epsilon-amino groups on tissue and plasma proteins

Beyond the preview

Go deeper on Hemopatch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemopatch.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call